Innate Pharma & IFLI: Fueling Follicular Lymphoma Innovation with $7.9M Investment

Innate Pharma, a leader in immuno-oncology, has received a significant boost with the Institute for Follicular Lymphoma Innovation (IFLI) announcing an up to $7.9M investment to support the development of IPH6501 in follicular lymphoma. This strategic alliance is set to drive innovation and improve patient outcomes in the relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) space.

Follicular lymphoma, the most common indolent B-cell NHL, accounts for 22% of cases in the Western world. The investment from IFLI will fund IPH6501's clinical trials, including the Phase 1/2 multicenter trial (NCT06088654), assessing its safety, tolerability, and efficacy in patients with relapsed and/or refractory CD20-expressing B-cell NHL. This trial aims to enroll up to 184 patients, further validating IFLI's confidence in IPH6501's potential.

IPH6501 is Innate Pharma's first-in-class CD20-targeting tetraspecific ANKET®, co-engaging CD20 on malignant B cells and three receptors on NK cells: NKp46, CD16, and the interleukin-2 receptor (via an IL-2 variant). This novel format delivers proliferation signals to NK cells, enhancing their effector functions against cancer cells. The investment from IFLI will also support further research to optimize IPH6501's dose and regimen in follicular lymphoma, potentially leading to improved patient outcomes.



The global non-Hodgkin lymphoma market is projected to reach $15.6 billion by 2025, with follicular lymphoma being a prominent subset. This investment positions IPH6501 to capture a significant share of this market if it receives regulatory approval. With its innovative approach of co-engaging multiple receptors on NK cells and targeting CD20 on malignant B cells, IPH6501 offers the potential for enhanced treatment efficacy and improved patient outcomes.

Innate Pharma's strategic alliance with IFLI aligns with its broader strategy to develop novel immunotherapies for cancer treatment. The ANKET® platform enables the creation of next-generation, multispecific natural killer (NK) cell engagers to treat certain types of cancer. This investment supports Innate's mission to develop innovative cancer therapies and potentially enhance its market position and shareholder value.



In conclusion, the up to $7.9M investment from IFLI in IPH6501 underscores the potential of Innate Pharma's innovative approach to follicular lymphoma treatment. This strategic collaboration positions IPH6501 to make a significant impact on the lives of patients with relapsed/refractory follicular lymphoma while driving growth and value for Innate Pharma shareholders. As Innate Pharma continues to advance its portfolio of novel immunotherapies, investors can expect further developments and opportunities in the immuno-oncology space.